In 2021 it paid to stay private when the chips were down

For biotech in 2021 it paid to be private. While waning public investor sentiment made the year a minor disaster for listed companies, closely held groups enjoyed their most successful 12 months ever, with secured venture capital eclipsing 2020’s then record-breaking total by 26%. READ MORE